An Early Phase 1 interventional study of Chicken extract supplement and Peptide Supplement in Cognitive Decline, Mild Cognitive Impairment and Aging, sponsored by Brand's Suntory Asia. Completed at 3 sites in Taiwan. Open to participants aged 55 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-16.
Sponsored by Brand's Suntory Asia · Early Phase 1, Interventional, and Prevention
This trial investigates the effect of a chicken extract supplement and a peptide supplement on cognitive function and potential mechanisms of action of cognitive decline during ageing, among non-demented elderly adults using a three-arm, randomized, placebo-controlled clinical trial design.
3,842 studies on the registry are indexed under Cognitive Dysfunction; 1,099 are open to participants now.
This study's enrollment of 276 is above the median of 65 across 2,807 interventional studies indexed under Cognitive Dysfunction.
Browse Cognitive Dysfunction studies →Brand's Suntory Asia is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Dietary Supplement: Chicken extract supplement
Dietary Supplement: Peptide Supplement
Other: Placebo
70ml of chicken extract supplement to be consumed daily in the morning before meals for 2 years.
70ml of Peptide Supplement (670mg) to be consumed daily in the morning before meals for 2 years.
70ml of placebo (caesinate) to be consumed daily in the morning before meals for 2 years.
Cognitive Function assessed by Alzheimer's Disease Composite Score (ADCOMS)
Change from baseline in Alzheimer's Disease Composite Score (ADCOMS). ADCOMS composite score is a weighted linear combination of the 12 items in the Wold's partial least squares (PLS) model. Composite scores range from 0.0 to a maximum of 1.97, where higher values indicate worse performance.
Time frame: 24 months
Florbetaben (18F) PET Scan Imaging
Change from baseline values in Florbetaben (18F) PET scan
Time frame: 24 months
Handgrip strength
Change from baseline in handgrip strength
Time frame: 12 months & 24 months
Ratio of plasma tau protein and amyloid-beta 42
Change from baseline in plasma tau protein \& amyloid-beta 42 ratio
Time frame: 24 months
Alzheimer's Disease Composite Score (ADCOMS)
Change from baseline in Alzheimer's Disease Composite Score (ADCOMS). ADCOMS composite score is a weighted linear combination of the 12 items in the Wold's partial least squares (PLS) model. Composite scores range from 0.0 to a maximum of 1.97, where higher values indicate worse performance.
Time frame: 12 months
Blood myeloperoxidase (MPO) levels
Change from baseline in blood myeloperoxidase (MPO) Higher levels of MPO indicate worse oxidative stress status
Time frame: 12 months & 24 months
Blood inflammation biomarker levels (hs-CRP, ESR, TNF-α, IL-6)
Change from baseline in inflammation, measured by the following blood biomarkers. Each biomarker will be evaluated individually. 1. High-sensitivity C-reactive Protein (hs-CRP) 2. Erythrocyte Sedimentation Rate (ESR) 3. Tumor necrosis factor alpha (TNFα) 4. Interleukin 6 (IL-6)
Time frame: 12 months & 24 months
Fasting blood glucose level
Change from baseline in fasting blood glucose level
Time frame: 4, 8, 12, 18 and 24 months
Taiwanese Depression Questionnaire (TQD) score
Change from baseline in patient-reported Taiwanese Depression Questionnaire (TQD) scores. TDQ scores range from 0 to 54, with the higher score indicating the greater depression state.
Time frame: 4, 8, 12, 18 and 24 months
Short Form-36 (SF-36) Component and Scale Scores
Change from baseline in Short Form-36 (SF-36) Component and Scale Scores. Each scale is directly transformed into a 0 - 100 scale on the assumption that each question carries equal weight. Lower score indicates more disability/worse health status.
Time frame: 4, 8, 12, 18 and 24 months
Athens Insomnia Scale (AIS)
Change from baseline in Athens Insomnia Scale Score. A composite score which ranges from 0-24 will be evaluated. Higher score stands for greater severity of insomnia.
Time frame: 4, 8, 12, 18 and 24 months
Incidence of infections
Number and incidence of infections occurring during the study period according to a self-reported infection survey
Time frame: 24 months, reported at each study visit (4, 8, 12, 18 and 24 months)
Cerebral blood flow measured with sonography
Mean values of cerebral blood flow measured with sonography
Time frame: 12 months & 24 months
Blood pressure (systolic blood pressure and diastolic blood pressure)
Change from baseline in systolic and diastolic blood pressure
Time frame: 4, 8, 12, 18 and 24 months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Brand's Suntory Asia